EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy of Ivabradine in Heart Failure Patients with a High-Risk Profile (Analysis from the SHIFT Trial)

Amr Abdin, Michel Komajda, Jeffrey S Borer, Ian Ford, Luigi Tavazzi, Cécile Batailler, Karl Swedberg, Giuseppe M C Rosano, Felix Mahfoud, Michael Böhm, SHIFT Investigators

ESC Heart Failure · 2023

DOI: 10.1002/ehf2.14455 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, 2023. Verfasst von Amr Abdin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Saarland University Medical Center, Kirrberger Strasse 100, Homb…. Hauptthemen laut MEDLINE: Ivabradine, Heart Failure, Stroke Volume, Ventricular Function, Left. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Early start and patient profile-oriented heart failure (HF) management has been recommended. In this post hoc analysis from the SHIFT trial, we analysed the treatment effects of ivabradine in HF patients with systolic blood pressure (SBP) < 110 mmHg, resting heart rate (RHR) ≥ 75 b.p.m., left ventricular ejection fraction (LVEF) ≤ 25%, New York Heart Association (NYHA) Class III/IV, and their combination. Methods and results The SHIFT trial enrolled 6505 patients (LVEF ≤ 35% and RHR ≥ 70 b.p.m.), randomized to ivabradine or placebo on the background of guideline-defined standard care. Compared with placebo, ivabradine was associated with a similar relative risk reduction of the primary endpoint (cardiovascular death or HF hospitalization) in patients with SBP < 110 and ≥110 mmHg [hazard ratio (HR) 0.89, 95% confidence interval (CI) 0.74–1.08 vs. HR 0.80, 95% CI 0.72–0.89, P interaction = 0.34], LVEF ≤ 25% and >25% (HR 0.85, 95% CI 0.72–1.01 vs. HR 0.80, 95% CI 0.71–0.90, P interaction = 0.53), and NYHA III–IV and II (HR 0.83, 95% CI 0.74–0.94 vs. HR 0.81, 95% CI 0.69–0.94, P interaction = 0.79). The effect was more pronounced in patients with RHR ≥ 75 compared with <75 (HR 0.76, 95% CI 0.68–0.85 vs. HR 0.97, 95% CI 0.81–0.1.16, P interaction = 0.02). When combining these profiling parameters, treatment with ivabradine was also associated with risk reductions comparable with patients with low-risk profiles for the primary endpoint (relative risk reduction 29%), cardiovascular death (11%), HF death (49%), and HF hospitalization (38%; all P values for interaction: 0.40). No safety concerns were observed between study groups.

Conclusions

Our analysis shows that RHR reduction with ivabradine is effective and improves clinical outcomes in HF patients across various risk indicators such as low SBP, high RHR, low LVEF, and high NYHA class to a similar extent and without safety concern.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IvabradineHeart FailureStroke VolumeVentricular Function, LeftHumansMaleFemaleAgedTreatment OutcomeMiddle AgedCardiovascular AgentsFollow-Up StudiesHeart RateDouble-Blind MethodSurvival RateBenzazepinesRisk Assessment

Stichwörter der Autor:innen

Heart failureHeart rateHigh riskIvabradineRisk indicators

Substanzen

IvabradineCardiovascular AgentsBenzazepines

Autor:innen und Institutionen

  • Department of Internal Medicine III, Cardiology, Angiology, Intensive Care Medicine, Saarland University Medical Center, Kirrberger Strasse 100, Homburg/Saar, 66421, Germany.
  • Department of Cardiology, Hospital Saint Joseph, Paris, France.
  • The Howard Gilman Institute for Heart Valve Diseases and Schiavone Institute for Cardiovascular Translational Research, State University of New York Downstate Health Sciences University, Brooklyn and New York, NY, USA.
  • Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
  • Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy.
  • Institut de Recherches Internationales Servier, Suresnes, France.

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Abdin, A., Komajda, M., Borer, J. S., Ford, I., Tavazzi, L., Batailler, C., Swedberg, K., Rosano, G. M. C., Mahfoud, F., Böhm, M., & SHIFT Investigators (2023). Efficacy of Ivabradine in Heart Failure Patients with a High-Risk Profile (Analysis from the SHIFT Trial). ESC Heart Failure. https://doi.org/10.1002/ehf2.14455

Vancouver

Abdin A, Komajda M, Borer JS, Ford I, Tavazzi L, Batailler C, et al. Efficacy of Ivabradine in Heart Failure Patients with a High-Risk Profile (Analysis from the SHIFT Trial). ESC Heart Failure. 2023. doi:10.1002/ehf2.14455

BibTeX
@article{Abdin2023,
  author = {Abdin, Amr and Komajda, Michel and Borer, Jeffrey S and Ford, Ian and Tavazzi, Luigi and Batailler, Cécile and Swedberg, Karl and Rosano, Giuseppe M C and Mahfoud, Felix and Böhm, Michael and SHIFT Investigators, SHIFT Investigators},
  title = {Efficacy of Ivabradine in Heart Failure Patients with a High-Risk Profile (Analysis from the SHIFT Trial)},
  journal = {ESC Heart Failure},
  year = {2023},
  doi = {10.1002/ehf2.14455}
}
Kostenlos starten →